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Abstract  
Interferon (IFN)-alpha, until recently the standard treatment of hepatitis C virus (HCV) 
infection, is associated with a significant risk of major depressive episode (MDE, or IFN-alpha-
induced depression). However, it is little studied the comparisons of clinical manifestations 
between IFN-alpha-induced depression and major depressive disorder (MDD). In addition, 
IFN-alpha induces different neuroinflammation and neuroendocrine status throughput the HCV 
treatment course; however, the clinical presentations have never been compared between early-
onset and later-onset IFN-alpha-induced depression. We assessed 200 HCV patients starting 
IFN-alpha therapy bi-weekly for 24 weeks, with the structured interview for confirmation of 
diagnosis of IFN-alpha-induced depression and with clinical rating scales for depressive 
symptoms and neuropsychiatric symptoms. Subjects developed IFN-alpha-induced depression 
(n=59, 30%) during the first 6 weeks of IFN-alpha therapy were defined as the early-onset 
group (n=32), while those developed depression after the 6th week were defined as the late-
onset group (n=27). A matched group of MDD patients (n=60) was used to compare specific 
clusters of depressive symptoms with early- and late-onset IFN-alpha-induced depression. 
Compared to the matched group of MDD patients, IFN-alpha-induced depression was 
significantly associated with more somatic symptoms and fewer symptoms of mood, anxiety 
and negative cognition. More somatic symptoms were also found in those who became 
clinically depressed at early stage of IFN-alpha therapy. We suggest that the specific somatic 
features of interferon-alpha-induced depression, and especially of early-onset depression, 
characterise individuals who are more sensitive to cytokines-induced changes in mood. 
 
  3 
Introduction  
Inflammation is increasingly recognized as contributing to the pathogenesis of 
depression, and the most strikingly supportive evidence for this inflammation theory is major 
depressive episode (MDE) induced by interferon (IFN)-alpha in patients with cancers or 
chronic viral infection (Chiu et al., 2017, Dantzer et al., 2008, Raison et al., 2006, Su, 2012). 
Chronic hepatitis C viral (HCV) infection is a major public health concern; however, the only 
standard treatment until recently, IFN-alpha in combination with ribavirin, is associated with 
significant risks of neuropsychiatric adverse effects. For example, up to 30% of patients 
develop IFN-alpha-induced depression (or major depressive episode according to DSM-IV 
diagnostic criteria) within the first 3 months (Schafer et al., 2007, Su et al., 2010, Udina et al., 
2012). These neuropsychiatric side effects result in early discontinuation and poor outcome of 
IFN-α therapy (Dusheiko, 1997, Leutscher et al., 2010, Renault et al., 1987). 
Substantiating the notion that IFN-alpha indeed induces major depression is that IFN-
alpha-induced depression (Raison et al., 2006): (i) is responsive to standard antidepressant 
therapy (Capuron et al., 2002a, Farah, 2002, Musselman et al., 2001); (ii) is associated with 
alterations in monoamine metabolism and its metabolic enzyme, indoleamine 2,3, 
dioxygenase (IDO) (Capuron et al., 2002b, Raison et al., 2009, Raison et al., 2010b, Wichers 
et al., 2005b); (iii) is associated with alterations in hypothalamic-pituitary-adrenal (HPA) axis 
function (Capuron et al., 2003b, Raison et al., 2010a, Raison et al., 2010c); and (iv) can be 
effectively prevented by antidepressant agents, including specific serotonin reuptake 
inhibitors (Jiang et al., 2014) and omega-3 fatty acids (Su et al., 2014).  
Clinically, it is interesting to know if there is any different clinical manifestation between 
the behavioral syndrome caused by innate immune cytokines and DSM-IV idiopathic major 
depressive disorder (MDD) in otherwise healthy individuals. Interestingly, in a previous study 
directly comparing symptom domains in patients with depression induced by IFN-alpha used 
for melanoma (n=9) and in physically healthy patients with major depressive disorder (MDD) 
(n=28), there were considerable overlaps for most of the clinical symptoms between the two 
groups. Patients with IFN-alpha-induced depression, however, had more motor retardation 
and weight loss, and less cognitive distortions, as compared with MDD patients (Capuron et 
al., 2009). While this study sheded some import light on the specific features of cytokine-
induced depression, it was limited by the small sample size, and confounded by the higher 
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IFN-alpha treatment dosage and the severe background disease of these patients, with 
malignant melanoma (Dieperink et al., 2000, Raison et al., 2005, Schaefer et al., 2002). 
Moreover, the depression rating scales were obtained at the time of maximum severity of 
depression rather than at the time of onset, thus making difficult to understand 
psychopathological differences between early-onset and later-onset IFN-alpha-induced 
depression, which may result from different sensitivity to cytokines and different molecular 
processes. Indeed, after the initial injection of IFN-alpha, almost all patients experience an 
acute sickness behaviour with flu-like symptoms and neuropsychiatric adverse effects induced 
by IFN-alpha (inflammation) (Capuron and Miller, 2004, Dieperink et al., 2000, Raison et al., 
2005, Trask et al., 2000), which resemble the effects of cytokine administration in animals 
and the somatic/vegetative symptoms in major depressive disorder (Dantzer et al., 2008, 
Raison et al., 2006, Su, 2009). Interestingly, psychological complications, including low 
mood, suicidal ideation, negative thoughts and attentional deficits occurs more commonly in 
the following weeks to months (Asnis and De La, 2006, Capuron et al., 2002a, Capuron et al., 
2002b, Dieperink et al., 2000, Raison et al., 2005). However, this potential shitf in depressive 
symptomatology over the course of IFN-alpha has not been investigated in patients that 
anyway fulfil diagnostic criteria for major depression, albeit at different time-points in the 
course of the treatment. 
To further explore the relationship between cytokines and depression, the aim of this 
study was to study the clinical phenotypes of n=59 patients with IFN-alpha-induced major 
depression used for chronic viral hepatitis, a much less disabling condition, and requiring a 
smaller dose of IFN-alpha, when compared with malignant melanoma; and of n=60 age- and 
gender-matched, physically healthy individuals with MDD. We specifically compared: 1) 
early-onset (before 6 weeks of treatment) and later-onset (after 6 weeks of treatment) IFN-
alpha-induced depression; and 2) IFN-alpha-induced depression with MDD in physically-
healthy individuals.  
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Materials and methods 
Subject 
Patients with chronic HCV were assessed for eligibility for IFN-alpha therapy by three 
hepatologists at the Liver Centre of the China Medical University Hospital, Taichung, Taiwan. 
Patients received combination therapy as their treatment for chronic HCV for 24 weeks (1.5 
µg of peg-IFN alpha-2beta per kilogram of body weight subcutaneously once weekly, and 
600–800 mg of ribavirin daily). Exclusion criteria included age over 70 years; prior IFN-alpha 
therapy; any autoimmune disorder; any cause for liver disease other than HCV; preganacy; a 
lifetime history of mania, antisocial personality disorder, or psychotic disorders; current use of 
antidepressants, antipsychotics and mood stabilizers; and any current psychiatric disorder, 
suicidality, and substance abuse or dependence. HCV patients who developed MDE at any 
follow-up assessment during the 24-week therapy are definded as the “IFN-DEP” group, 
while HCV patients who did not develop MDE are definded as the “IFN-NON-DEP” group. 
In addition, the subjects developed IFN-alpha-induced depression at the assessments of the 
2nd, 4th and 6th weeks of IFN-alpha therapy were defined as the Early IFN-DEP group, while 
those developed depression after the 6th week were defined as the Late IFN-DEP group. 
Sixty-three percent of the patients in this study were part of the samples previously published 
in our genetic association study (Su et al., 2010). 
By matching sex and age to the IFN-DEP group, medically healthy individuals with 
major depressive disorder (definded as “MDD” group) were enrolled from the psychiatric 
outpatient clinic at the same hospital. Eligible patients who met the diagnostic criteria of 
DSM-IV for MDD were between 18 and 70 years old, physically healthy on medical history 
and physical examination and laboratory parameters within normal limits, and free from 
antipsychotics, antidepressant, and anticonvulsant medications for more than 2 weeks. 
Exclusion criteria included pregnancy; comorbidity of any suspected current Axis I disorders 
or suicidality; and any lifetime history of mania, antisocial personality disorder, or psychotic 
disorders. After complete explanation of the study to the subjects, written informed consents 
were obtained. The study was approved by the China Medical University Hospital 
Institutional Review Board. Data were collected from July 2008 to June 2011. 
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Experimental design 
This was a 24-week, prospective, observerational study. Before starting the study, the 
hepatologists gave brief information to all volunteered HCV patients about this study and 
referred them to the researchers. The researchers then provided structured information about 
IFN-alpha-induced neuropsychiatric adverse effects and depression, and the procedure of this 
study. Patients had to fully understand and sign the informed consent before enrolment.  
Patients were evaluated assessed bi-weekly for 24 weeks of IFN-alpha therapy. At each 
assessment, patients were assessed with the structured Mini International Neuropsychiatric 
Interview for DSM-IV Axis I Disorders (MINI) (Sheehan et al., 1998) for confirmation of 
diagnosis of MDE, with the 21-item Beck Depression Inventory (BDI) for depressive 
symptoms, and with the self-reported Neurotoxicity Rating Scale (NRS) (Valentine et al., 
1995)and the Chalder Fatigue Questionnaire (Chalder et al., 1993) for other neuropsychiatric 
symptoms. Sociodemographic factors were recorded. Any adjunctive treatment was decided 
by treating physicians according to their clinical judgement and was not controlled by our 
study protocol.  
For HCV patients who developed IFN-alpha-induced depression, the semi-structured 
version of 21-item Hamilton Depression Rating Scale (HDRS) (Hamilton, 1960) was applied 
to assess the severity of different clusters of depressive symptoms at the time when MDE 
diagnosis was made. The HDRS was also used in the matched group of MDD patients. The 
HRSD items were divided into the following clusters: Core (items 1, 2, 7, 8, 10, 13), Sleep 
(items 4, 5, 6), Psychic Anxiety (items 9, 10), Somatic Anxiety (items 11, 12, 13), and 
Cognition (items 2, 15, 20) (Serretti et al., 1998, Serretti et al., 2007).  
Psychometric measurements 
The Mini-International Neuropsychiatric Interview (MINI) was applied for the detection 
new onset cases of major depressive episode during IFN-alpha therapy. MINI is a short 
structured diagnostic interview for psychiatric disorders according to the Diagnostic and 
Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) and the International Statistical 
Classification of Diseases and Related Health Problems 10th Revision (ICD-10). With an 
administration time of approximately 15 minutes, the MINI was designed to meet the need for 
a short but accurate structured psychiatric interview for multicenter clinical trials and 
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epidemiology studies and to be used as a first step in outcome tracking in non-research 
clinical settings (Sheehan et al., 1998). The information of translation, validation and 
instruction of Taiwanese version of MINI can be accessed on the website of Taiwanese 
Society of Psychiatry (http://www.sop.org.tw/dow_a.htm). This Taiwanese version had been 
shown a very good validation and inter-rater reliability after being retranslated into English, 
with the kappa value of 0.75, Z score value of 13.22 (Chou et al., 2007). The Taiwanese 
version of MINI has been used extensively, by us and others, in many clinical trials and 
epidemiology studies in Taiwan (Chou et al., 2007, Hsiao et al., 2002, Su et al., 2007, Su et 
al., 2010, Su et al., 2014, Teng et al., 2005). 
The Depression Inventory (BDI) is a commonly used, self-administered, instrument in 
screening and severity-rating in depression (Beck et al., 1961). The second edition of BDI has 
been developed in 1996 to address all of the nine DSM-IV criteria for a major depressive 
episode (Beck et al., 1996). The second edition of BDI has been translated into multiple 
languages as well as Traditional Chinese in Taiwan, with a good validity and reliability of 
Cronbach’s α of 0.94 (Lu et al., 2002).  
The Neurotoxicity Rating Scale (NRS) is a checking-list questionnaire, with each item 
rated from 0 to 10 as a visual analogue scale, and is used for the evaluation of 39 
neuropsychiatric symptoms related to cytokine therapy (Valentine et al., 1995). The 
developers, Professors Meyes and Valentine, did not develop any scoring system for the rating 
scale (personal communication), and used it only as an adverse effect checking list. In our 
study, we used the rating method of 0 to 10 for each item, like a visual analogue scale, as is 
suggested by the developer (personal communication). The NRS was translated into 
Traditional Chinese by the author, K.-P. Su, together with an American born Taiwanese 
nutritionist who is fluent in Chinese and English. The preliminary Traditional Chinese 
translation was then back-translated by the other two bilingual Taiwanese psychiatrists who 
are fluent in Chinese and English. Both of them were bicultural experts and were not given 
any information about the NRS. The back-translation was then discussed and reviewed by all 
researchers. We repeated the translation and back-translation procedures until complete 
agreement between English and Traditional Chinese versions was obtained.  
The Chalder Fatigue Questionnaire (CFQ) has been developed and widely used both to 
measure the severity of fatigue and as an aid for assessing patients with Chronic Fatigue 
Syndrome (Chalder et al., 1993). The CFQ was translated into Traditional Chinese by the 
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author, KP-Su, together with an American born Taiwanese nutritionist who is fluent in 
Chinese and English. The preliminary Traditional Chinese translation was then back-
translated by the other two bilingual Taiwanese psychiatrists who are fluent in Chinese and 
English. Both of them were bicultural experts and were not given any information about the 
CFQ. The back-translation was then discussed and reviewed by all researchers. We repeated 
the translation and back-translation procedures until agreement between the English and 
Traditional Chinese versions was obtained.  
Outcome measurement and Statistic analysis 
The independent-samples t or chi-square tests were used to compare continuous 
variables between IFN-DEP and IFN-NON-DEP groups. Logistic regression analysis was 
performed to find the predictors of the occurrence of IFN-alpha-induced depression. The 
effects of time (psychological measurements over times) and group (HCV patients with or 
without IFN-alpha-induced depression), as well as the time and group interaction, on the 
changes of BDI, NRS and CFQ scores were assessed with repeated measurement analyses in 
general linear modelling.  
Univariate analysis of variance (ANOVA) was used to compare differences in HRSD 
symptoms among IFN-DEP, IFN-NON-DEP and MDD groups. The post hoc analyses for 
between-group comparisons were performed using Tukey test for pairwise comparisons. The 
“group” effect (IFN-DEP, IFN-NON-DEP and MDD groups) on HRSD symptoms was 
estimated with multivariate analysis of variance employing general linear modelling 
(MANOVA). Whenever appropriate, data were reported as Mean±SD and the error bars were 
represented as standard error of the means (SEM) in the result figures. All data were analyzed 
using the SPSS version 15 statistical software (SPSS Inc., Chicago, Illinois, USA). P values 
less than 0.05 were considered statistically significant.  
 
Results 
The incidence rate of IFN-alpha-induced depression 
Two hundred and twenty-nine patients were referred. Thirteen from the 229 eligible 
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patients who had current psychiatric disorders (5 with major depressive disorder and 8 with 
general anxiety disorder) were excluded. Sixteen withdrew consent or were lost in follow-up 
visits. Two hundred (87.3%) from 229 consent patients were completed the 24-week follow-
up during IFN-alpha therapy. Men (n=112) comprised 56% of the sample. Mean age was 50 
years (SD, 11; range, 22–70 years). At baseline, no enrolled patient either met criteria for any 
current psychiatric disorder or took any psychotropic medication.  
------------------------------- 
Insert Figure 1 about here 
------------------------------- 
Fifty-nine patients developed IFN-alpha-induced depression (29.5%, IFN-DEP group) at 
any point during the 24-week therapy, while 141 patients did not develop IFN-alpha-induced 
depression (70.5%, IFN-NON-DEP group). Figure 1 presents the cumulative percentages of 
patients that developed IFN-alpha-induced depression at the follow-up visits during 
IFN/ribavirin therapy. The numbers (percentages) of new cases of IFN-alpha-induced 
depression at weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24, were 11 (5.5%), 12 (6%), 9 
(4.5%), 14 (7%), 4 (2%), 2 (1%), 2 (1%), 2 (1%), 1 (0.5%), 1 (0.5%), 1 (0.5%) and 0 (0%), 
respectively.  
Comparison of symptomatology among patients with IFN-alpha-induced depression before 
and after 6-week IFN-alpha therapy and patients with major depressive disorder 
We compared clinical characteristics and symptom clusters of HDRS between the 3 
groups from patients who developed IFN-alpha-induced depression within 6 weeks of IFN-
alpha therapy (Early IFN-DEP group), or after 6 weeks (Late IFN-DEP group), or the gender- 
and age-matched patients with MDD. The HDRS scores and subscores of patients with IFN-
induced depression were recorded at the time when MDE diagnosis was made. There were no 
significant differences in gender (chi-square=1.3, p=0.52) and age (p=0.2) among the Early 
IFN-DEP group (n=32 with 15 males), the Late IFN-DEP group (n=27 with 11 males), and 
the matched MDD group (n=60 with 25 males). In MANOVA analyses, there were significant 
effects of group (F=9.3, p<0.001) on expression of cluster symptoms in HRSD. Furthermore, 
the simple main effects and post hoc comparisons revealed group differences were significant 
in Core (F=10.6, p<0.001), Psychic Anxiety (F= 16.5, p<0.001), Somatic Anxiety (F= 23.8, 
  10 
p<0.001) and Cognition (F= 6.2, p=0.003) symptom clusters, but not in total HDRS scores 
(F=0.2, p=0.78) or in the Sleep symptom cluster (F=0.6, p=0.53).  
Table 1 presents the between-group comparisons for scores of specific symptom clusters 
between the Early IFN-DEP group, the Late IFN-DEP group, and the MDD group. Compared 
to the MDD patients, the Early IFN-DEP patients had more Somatic Anxiety and less Core 
symptoms, less Psychic Anxiety, and less Cognition symptom. In addition, the Early IFN-DEP 
patients had more Somatic Anxiety and a trend for less Core symptoms (p=0.09), than the Late 
IFN-DEP patients. The Late IFN-DEP and MDD patients were not significantly different, 
except for less Psychic Anxiety in the Late IFN-DEP group.  
------------------------------- 
Insert Table 1 about here 
------------------------------- 
We compared the demographic characteristics and baseline clinical manifestitations 
between Early and Late IFN-DEP groups (not shown in the Tables). There were no significant 
differences between groups in gender distribution (χ2=0.22, p=0.6), age (p=0.09), education 
years (p=0.7), marital status (χ2=0.01, p=0.92) and history of major depression (χ2=2.62, 
p=0.11). For baseline (before starting the IFN-alpha) depressive, fatigue, and neuropsychiatric 
symptoms, the Early IFN-DEP group had higher BDI (7.8±7.5 vs. 3.8±4.0, p<0.001), but only 
slightly higher CFQ (9.7±8.2 vs. 8.1±9.8, p=0.4) and NRS (45.9.7±56.8 vs. 28.9±41.1, 
p=0.2), as compared with the Late IFN-DEP group.  
------------------------------- 
Insert Figure 2 about here 
------------------------------- 
Figure 2 presents the mean (±SEM) scores of BDI (Figure 2A), CFQ (Figure 2B) and 
NRS (Figure 2C) scores at weeks 0, 2, 4, 8, 12 and 24 of IFN-alpha therapy in Early and Late 
IFN-DEP and IFN-NON-DEP groups. Given the impact of early development of depressive 
and neuropsychiatric symptoms on IFN-alpha-induced depression, we compared the early 
changes in scores of BDI, NRS and CFQ between baseline and week 2. We found that those 
who later developed IFN-alpha-induced depression (either early or late onset) showed a 
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greater increase in BDI (8.0±9.2, or 145%), CFQ (5.9±6.4, or 66%) and NRS (41.5±39.0, or 
108%) scores, while those who did not develop depression had no, or much smaller increases 
in BDI (0.4±6.7, or 8.5%), CFQ (0.4±6.0, or 5.9%) and NRS (2.7±31.1, or 10%). The 
differences in these increases between IFN-DEP and IFN-NON-DEP groups are all significant 
(all p<0.001). Interestingly, when comparing the early changes between Early and Late IFN-
DEP groups, both groups showed increases in BDI (9.1±8.8 and 7.0±10.1), CFQ (6.8±6.3 and 
4.6±6.6) and NRS (48.6±45.0 and 30.6±25.2) scores, but only the difference in NRS changes 
reached the significant level (p=0.045).   
 
Discussion 
To our knowledge, this is the first study to compare clinical manifestations between 
early-onset and later-onset IFN-alpha-induced depression, and the largest such study 
comparing patients with IFN-alpha-induced depression and physically health individuals with 
‘psychiatric’ MDD. We found that patients who develop IFN-alpha-induced depression before 
6 weeks of IFN-alpha therapy have different phenotypes of depressive symptoms compared 
with both patients with later onset IFN-alpha-induced depression and patients with MDD. 
According to the results of Table 1, those who become clinically depressed at an early stage of 
IFN-alpha therapy have more somatic symptoms than those who become clinically depressed 
later and than patients with MDD. Furthermore, early-onset, but not late-onset, IFN-alpha-
induced depression, is associated with less core depressive and cognitive symptoms than 
MDD.  
Our findings are consistent with the only one previous small-scale study directly 
comparing symptom domains in malignant melanoma patients with IFN-alpha-induced 
depression (n=9) to MDD (n=28), in which they reported more motor retardation and less 
cognitive distortions in IFN-alpha-induced depression as compared to MDD (Capuron et al., 
2009). We here demonstrate that these observations apply in particular to patients who 
develop IFN-alpha-induced depression early on, although interesting in this study the time of 
maximum depression occurred after an average of 7 ± 3 weeks of IFN-alpha treatment 
(Capuron et al., 2009), suggesting that all cases had an onset before week 6. The higher dose 
of IFN-alpha in the study by Capuron, due to its use for melanoma rather than for viral 
hepatitis, could explain this more rapid onset.  
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It has been proposed that the somatic symptoms might be “the outward manifestation of 
sensitization of the brain cytokine system that is normally activated in response to activation 
of the innate immune system and mediates the subjective, behavioural and physiological 
components of sickness (Dantzer, 2005).” Indeed, somatic symptoms in patients with or 
without depression are similar to the symptoms of “sickness behavior” induced by acute 
cytokine administration (Chang et al., 2017, Su, 2008, 2009, 2012), and may be underpinned 
by different biological mechanisms compared with more psychological and cognitive 
symptoms of depression. For example, we have previously shown that an inflammation-
related genetic variation, the phospholipase A2 BanI GG genotype, is associated with more 
somatic symptoms of depression in both patients with IFN-alpha-induced depression and in 
physically-healthy patients with MDD (Chang et al., 2018, Su et al., 2010). In contrast to the 
acute inflammatory reaction, later stages of IFN-alpha administration is associated with a 
recovery of initial inflammatory reaction (Capuron et al., 2003a, Capuron et al., 2003b, 
Felger et al., 2007) and a development of tryptohan/monoamine dysregulation, which is 
particularly associated with the development of the more psychological and cognitive 
symptoms (Capuron et al., 2002b) such as low mood, suicidal ideation, negative thoughts and 
attentional deficits (Asnis and De La, 2006, Capuron et al., 2002a, Capuron et al., 2002b, 
Dieperink et al., 2000, Raison et al., 2005). The findings from our present study imply that 
differential sensitivity to the inflammatory challenge, or to its downstream mediators like the 
tryptohan/monoamine dysregulation, may lead to the onset of depression in different people 
and at different stages; in particular, who develop early-onset depression seems to have a 
combination of more severe psychopathology before starting IFN-alpha (statistically 
significant for BDI) and more severe increases in psychopathology during the first two weeks 
(statistically significant for NRF). 
It has been reported that the development of depressive and neuropsychiatric symptoms 
in the early stage of IFN-alpha therapy can predict later development of major depression. For 
example, cancer patients who later developed IFN-alpha-induced depression displayed a 
higher increase in scores of the items of depressed mood, anorexia, fatigue and 
gastrointestinal symptoms at the first 2 weeks of IFN-alpha therapy (Capuron et al., 2002a, 
Whale et al., 2015). The impact of the early development of vegetative symptoms has been 
also reported in previous studies (Robaeys et al., 2007, Wichers et al., 2005a). In agreement 
with those results, our present study also found that the early increases in depressive (BDI), 
neuropsychiatric (NRS) and fatigue (CFQ) symptoms at the first 2 weeks predicted future 
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onset of IFN-alpha-induced depression.  
The incidence rate of IFN-alpha-induced depression in Taiwan 
Although not the main aim of the study, it is worth commenting on the fact that this is 
the largest study examining the incidence of IFN-alpha-induced depression in a Han Chinese 
population. We found an incidence of 29.9%, a finding that is consistent with most 
prospective studies, in which the occurrence rates ranged from 20% to 45% (Beratis et al., 
2005, Bonaccorso et al., 2002a, Bonaccorso et al., 2002b, Constant et al., 2005, Hauser et al., 
2002, Horikawa et al., 2003, Lotrich et al., 2007, Maddock et al., 2005, Miyaoka et al., 1999, 
Robaeys et al., 2007, Wichers et al., 2005a). In general, the diagnosis of major depressive 
episode from earlier studies was mostly based on non-structured interviews, resulting in 
higher occurrence rates from 41% to 45% (Bonaccorso et al., 2002a, Miyaoka et al., 1999). 
There were 2 studies using the structured interview, SCID, at lease once at month in the first 
three months. The incidence rates were 20% in the study with 60 patients of chronic hepatitis 
B and C (Maddock et al., 2004) and 39% in the other study with only 23 patients with chronic 
HCV (Lotrich et al., 2007). The MINI was applied as diagnostic tools by Wichers’s group, 
reporting an occurrence rate of 31%. That study was, however, also limited by its very small 
sample size (n=16) (Wichers et al., 2005a).  
Limitations 
There are methodological considerations and study limitations. Firstly, when using 
MINI as screening tool for major depressive episode, we focused on occurrence of major 
depressive episode during IFN-alpha therapy. Hence, the incidence of other IFN-alpha-
induced psychiatric disorders, including manic episode and other psychotic disorders, was 
theoretically unknown. The patients, however, received regular clinical follow-up, and indeed 
we identified a patient who developed a manic episode (Wu et al., 2007). Therefore, we are 
confident that if psychotic or manic episodes had developed in the populations, we would 
have been alerted by the clinicians. Secondly, most of the patients with IFN-alpha-induced 
depression were detected quite early in the course of their depressive episode, usually by 2-4 
weeks from onset; patients with MDD, however, had much longer duration of their clinical 
illness (mean=17.4 weeks and SD=13.2 weeks, not shown in the Results). The difference 
among groups might not be ruled out to be associated with the illness duration. Thirdly, there 
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is no consensus to define the “early- and late-onset” IFN-alpha-induced depression or “early 
changes” of depression or other neuropsychiatric syndromes. In current study, we applied the 
cut-off point at week 6 for clinical diagnosis and week 2 for early syndromes mainly for 
practical considerations. As it takes 2 weeks with full syndrome to meet the diagnostic 
criteria, it might be proper to define as the development of early neuropsychiatric syndromes 
but it would be too early to define clinical MDE diagnosis at weeks 2 or 4. In addition, the 
cut-off point at week 6 makes the subgroups more even (n=32 for early versus n=27 for late) 
in current study, which could increase the statistic powers. Fourthly, due to the observational 
nature in design, this study is limited by the lack of control of adjunctive treatments. The 
clinicians prescribed all kind of adjunctive treatments very commonly, such as acetaminophen 
for headache and fever, antihistamines for nasal obstruction and rhinorrhea, benzodiazepines 
for insomnia and anxiety, antiemetic for nausea, loperamide and bismuth subsalicylate for 
diarrhea, erythropoetin for hemolytic anemia…etc. As the adjunctive treatments were widely 
distributed and closely associated with patients’ condition and clinicians’ decisions, we don’t 
think it is proper to be controlled for the changes of psychopathological changes or compared 
between groups in statistical adjustments in study analyses. Finally, the lack of reliability and 
validity tests of Taiwanese version of self-reported NRS and CFQ should be addressed as a 
methodology limitation in of our research.  
In conclusion, IFN-alpha-induced depression, especially the early-onset subgroup, is 
associated with more somatic symptoms and less core depressive, anxious and cognitive 
symptoms, indicating that different biological mechanisms, and potentiall different sensitivity 
to an inflammatory challenge.  
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Figure 1. The cumulative incidence rate of patients who developed IFN-alpha-induced 
depression at some point during 24-week treatment period 
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Table 1. Mean±SD scores of specific symptom clusters from the semi-structured version of 
21-item Hamilton Depression Rating Scale (HDRS) in patients with early- versus late-onset 
IFN-alpha-induced depression and paitents with major depressive disorder (MDD) 
 Early IFN-DEP 
(n=32) 
Late IFN-DEP 
(n=27) 
MDD 
(n=60) 
HDRS total scores 21.2±3.5 21.8±4.6 21.8±4.3 
HDRS symptom clusters 
   
Core (items 1, 2, 7, 8, 10, 13) 7.5±1.8 ** 8.5±1.7 9.4±2.0 
Psychic anxiety (items 9, 10) 1.4±1.2 ** 1.9±1.0 ++ 2.9±1.2 
Cognition (items 2, 15, 20) 1.6±1.0 * 1.8±1.0 2.4±1.2 
Sleep (items 4, 5, 6) 3.9±1.4 3.9±1.6 3.6±1.8 
Somatic Anxiety (items 11, 12, 13) 5.9±0.9 ** ^ 4.9±1.4  4.2±1.2 
Between groups comparisons with independent-samples t test results: *p<0.01; **p<0.001 for 
comparisons of MDD subjects to IFN-alpha-treated depressed subjects onset by the 6th week 
(Early IFN-DEP); ++p<0.001 for for comparisons of MDD subjects to IFN-alpha-treated 
depressed subjects onset after the 6th week (Late IFN-DEP); ^p<0.01 for comparisons of 
Early IFN-DEP to Late IFN-DEP  
Abbreviations: SD=standard deviation; IFN=interferon 
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Figure 2. Beck Depression Inventory (BDI, A), Chalder Fatigue Questionnaire (CFQ, B) 
and Neurotoxicity Rating Scale (NRS, C) and scores of patients without (n=141) and 
with early- (n=32) and late-onset (n=27) IFN-alpha-induced depression during 24-week 
treatment period 
 
The mean±standard error of the mean (SEM) scores of BDI, CFQ and NRS at weeks 0, 2, 4, 
8, 12 and 24 of IFN-alpha therapy in groups of patients without (IFN-NON-DEP) and with 
early- (early IFN-DEP) and late-onset (late IFN-DEP) IFN-alpha-induced depression (IFN-
NON-DEP).  
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